Does Aetna (CVS Health) Cover Tresiba (Insulin Degludec)?

What Tresiba Is and Why Aetna Reviews It Carefully

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours in clinical pharmacology studies. The FDA approved insulin degludec in September 2015 for glycemic control in adults and children with type 1 diabetes (T1D) and type 2 diabetes (T2D). A pediatric indication for patients aged 1 year and older followed in 2017.

Because Tresiba costs considerably more than older basal insulins such as glargine U100 (Lantus, generic) or detemir (Levemir), Aetna places it on a higher formulary tier and requires prior authorization before dispensing. The insurer's pharmacy and therapeutics committee evaluates whether cheaper alternatives have been tried. This is standard managed-care practice, not a unique barrier specific to Tresiba.

The DEVOTE trial (N=7,637) published in the New England Journal of Medicine demonstrated that insulin degludec produced a 40% lower rate of severe hypoglycemia compared to glargine U100 (HR 0.60; 95% CI 0.48 to 0.76; P<0.001 for superiority) while achieving non-inferiority for major adverse cardiovascular events. DEVOTE, NEJM 2017. That hypoglycemia advantage is the central clinical argument physicians use when writing prior authorization letters for Aetna.

What Formulary Tier Is Tresiba on Aetna Plans?

Tresiba lands on Tier 3 or Tier 4 depending on the specific Aetna plan year and whether the employer has adopted CVS Caremark's commercial formulary.

On the CVS Caremark standard commercial formulary, insulin degludec is listed as a non-preferred brand in most plan designs, placing it on Tier 3 or Tier 4. Tier 3 copays average $60 to $100 per 30-day supply after deductible; Tier 4 copays can reach $150 or more. Aetna's Medicare Part D plans may list it differently, and Aetna Medicaid plans follow state-specific preferred drug lists.

The American Diabetes Association 2024 Standards of Care recommend that formulary tier placement should not override individualized clinical decisions, stating: "Insulin access and affordability are critical, and clinicians should advocate for their patients when insurance barriers interfere with optimal therapy." This position supports appeals when a plan's tier structure conflicts with patient-specific hypoglycemia risk.

For the most accurate tier information for a given patient, providers should query the Aetna provider portal or call the pharmacy benefits line at the number on the member's ID card, because employer-sponsored plan designs vary widely from the base Aetna formulary. FDA prescribing information for insulin degludec lists the approved concentrations (100 units/mL and 200 units/mL FlexTouch pens) that a PA request must specify precisely to avoid processing errors.

Does Aetna Require Prior Authorization for Tresiba?

Yes. Prior authorization is required on essentially every Aetna commercial plan that covers Tresiba. The process is moderate-to-high difficulty because Aetna's criteria typically demand documentation of several specific clinical items before approval.

Standard Aetna prior authorization criteria for insulin degludec include:

• A confirmed diagnosis of T1D or T2D with documented HbA1c
• Prescriber attestation that the patient requires a basal insulin
• Evidence that the patient tried and failed, or has a documented contraindication to, at least one preferred basal insulin (usually glargine U100 or biosimilar glargine)
• For hypoglycemia as the step-therapy exception: documented episodes of clinically significant hypoglycemia (blood glucose <54 mg/dL or severe events requiring third-party assistance) on the preferred agent
• Current medication list and any other diabetes medications the patient is taking

The FDA's approved labeling notes that insulin degludec has a flatter pharmacokinetic profile than glargine U100, which is the pharmacological basis for its lower hypoglycemia rates documented in DEVOTE. Citing this labeling directly in the PA letter strengthens the clinical rationale.

PA approvals are typically valid for 12 months, after which re-authorization is required. Aetna targets a 72-hour turnaround for standard PA requests and 24 hours for urgent requests, per CMS regulations governing Medicare Advantage prior authorization timeframes. Commercial plan timelines are similar but governed by state prompt-pay laws rather than CMS rules. A 2023 JAMA study found that prior authorization delays in insulin access were associated with a 25% higher rate of acute diabetic complications, underlining the clinical stakes of a slow PA process.

Does Aetna Require Step Therapy Before Tresiba?

Step therapy is required in most cases. Aetna generally requires a trial of at least one lower-tier basal insulin before Tresiba will be approved. The preferred step agents are typically glargine U100 (including biosimilars such as Basaglar or Semglee) or insulin detemir.

Step therapy exceptions exist and are clinically important. Aetna must consider a step therapy exception when:

1. The patient documented a clinically significant adverse reaction to the preferred agent
2. The preferred agent is contraindicated per FDA labeling
3. The prescriber documents that the preferred agent is expected to be ineffective based on the patient's clinical history
4. The patient is stable on Tresiba and switching would create medically harmful instability

Several states have enacted step therapy override laws that require insurers to grant exceptions within defined timeframes. Patients in states such as New York, Texas, and Virginia have statutory rights to expedited step therapy override decisions. The National Conference of State Legislatures tracks step therapy laws by state and is a useful resource for prescribers preparing an override request.

A 2022 Annals of Internal Medicine analysis of basal insulin switching found that patients forced to switch from a long-acting analog to a shorter-duration alternative experienced a mean HbA1c increase of 0.4 percentage points and a 31% higher rate of hypoglycemic events in the first 90 days. This data is directly applicable to step therapy exception letters for patients already stable on Tresiba.

HealthRX Step-Therapy Exception Framework for Tresiba PA Letters

| Scenario | Supporting Evidence to Include | Expected Outcome | |---|---|---| | Hypoglycemia on glargine | CGM or glucometer logs, ER visit records, glucagon use | Strong. DEVOTE HR 0.60 cited directly | | Nocturnal hypoglycemia specifically | Sleep-hour glucose records, CGM overnight trace | Strong. Degludec's flat PK profile is directly relevant | | Prior glargine trial with HbA1c failure | Labs showing HbA1c above target despite dose optimization | Moderate. Requires dose titration documentation | | New-start T1D patient, no prior basal | Clinical justification for starting at degludec | Moderate-to-low. Harder without trial documentation | | Stable on Tresiba, switching risk | Prescriber letter citing instability risk | Moderate. Stronger with documented prior instability |

How to Appeal an Aetna Denial of Tresiba

Aetna denials of Tresiba follow a two-level appeal process. Getting the appeal right the first time matters because each level has strict deadlines.

Level 1: Internal Appeal. File within 180 days of receiving the denial notice (for commercial plans). Submit a written appeal with:

• The denial letter and Aetna's stated reason for denial
• A clinical letter from the prescriber addressing each denial criterion specifically
• Supporting clinical records (HbA1c history, hypoglycemia logs, CGM data if available)
• Published literature supporting degludec over the denied alternative. DEVOTE (NEJM 2017) is the anchor citation
• A copy of the FDA label noting the clinical differentiation

Aetna must respond to a standard internal appeal within 30 days. Urgent appeals get a 72-hour response. A 2021 JAMA Internal Medicine study found that 39% of insurer denials are overturned on internal appeal when the physician submits peer-reviewed evidence alongside the clinical record.

Level 2: External Independent Review. If Aetna denies the internal appeal, the patient has the right to request an external independent review organization (IRO) review. IRO decisions are binding on Aetna under the ACA's external review requirements. The ACA external review rules mandate that insurers comply with the IRO decision. Approval rates at the IRO level for clinically well-documented insulin cases run roughly 45 to 55% based on published insurer accountability data from several state insurance departments.

The American Diabetes Association's Standards of Care explicitly state that "providers should be aware of and utilize available appeal and exception processes when formulary restrictions limit access to necessary diabetes medications." Citing this guideline in the IRO appeal letter signals to reviewers that a national clinical authority supports the prescriber's position.

For Medicare Advantage patients, the timeline differs. Standard appeals require a decision within 30 days; expedited appeals within 72 hours. The CMS Medicare Advantage appeals guidance outlines exact steps and timelines.

What Does Tresiba Cost Without Aetna Approval?

The list price for Tresiba 100 units/mL FlexTouch (5 pens, 300 units each) is approximately $510 per month. Very few patients pay this amount in practice, because multiple cost-reduction options exist.

The Novo Nordisk Patient Assistance Program offers Tresiba at no cost to uninsured patients who meet income criteria (typically at or below 400% of the federal poverty level). For commercially insured patients whose Aetna plan denies coverage, the Novo Nordisk savings card reduces out-of-pocket cost to as low as $35 per month for eligible patients. Eligibility restrictions apply and the card cannot be used with any federal or state government insurance program (Medicare, Medicaid, TRICARE).

Mark-Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently list insulin degludec at a significantly reduced price relative to the manufacturer savings program, making the Novo Nordisk card the superior option for most commercially insured patients awaiting appeal resolution.

A 2023 Health Affairs analysis of insulin affordability found that cost-sharing above $35 per month was associated with a 23% higher rate of insulin rationing behaviors, including dose reduction and skipped injections, with direct increases in emergency department utilization. This data is relevant when making the case to Aetna that delayed access has measurable downstream costs.

What Clinical Data Supports Prescribing Tresiba Over Other Basals?

The clinical case for insulin degludec rests on three well-documented advantages: lower hypoglycemia rates, a flatter and more predictable pharmacokinetic profile, and flexible dosing timing.

DEVOTE (N=7,637) is the most cited. In this double-blind cardiovascular outcomes trial, degludec achieved non-inferiority to glargine U100 for MACE (HR 0.91; 95% CI 0.78 to 1.06) while producing statistically significant reductions in severe hypoglycemia (HR 0.60; P<0.001). DEVOTE full publication, NEJM 2017.

The BEGIN Basal-Bolus Type 1 trial (N=629) found that degludec produced similar HbA1c reduction to glargine U100 in T1D patients but with a 25% lower rate of nocturnal hypoglycemia (P<0.05). BEGIN Basal-Bolus Type 1, PubMed. For T1D patients with documented nocturnal hypoglycemia on glargine, this trial is a strong component of the PA and appeal package.

The FDA prescribing information notes the half-life of insulin degludec is approximately 25 hours at steady state, compared to roughly 12 hours for glargine U100. This pharmacokinetic difference translates to the clinical outcomes seen in DEVOTE and BEGIN.

The Endocrine Society's Clinical Practice Guideline on Diabetes Pharmacotherapy recommends ultra-long-acting insulins such as degludec or glargine U300 for patients with recurrent hypoglycemia on standard basal insulins, a recommendation directly applicable to Aetna PA exception requests. The guideline states: "For patients with type 1 or type 2 diabetes who experience problematic hypoglycemia on glargine U100, switching to degludec or glargine U300 reduces hypoglycemia without compromising glycemic control."

A 2020 real-world study in Diabetes Care (N=14,817 propensity-matched patients) confirmed DEVOTE findings in a non-trial population, showing a 32% lower rate of emergency department visits for hypoglycemia among degludec users versus glargine U100 users over 12 months (P<0.001).

Tresiba for Type 1 vs. Type 2 Diabetes: Does the Aetna Criteria Differ?

Aetna applies slightly different clinical thresholds depending on the diabetes type. The underlying step therapy requirement is the same, but the evidentiary bar for exceptions differs in practice.

For T1D patients, the clinical argument is somewhat easier to make because T1D carries an inherently higher hypoglycemia risk. The ADA 2024 Standards of Care note that hypoglycemia unawareness affects approximately 20 to 40% of people with longstanding T1D, and these patients are at highest risk from the pharmacokinetic variability of shorter-acting basals. Documenting impaired hypoglycemia awareness (Clarke score or Gold score) in the PA letter is a high-yield move for T1D patients.

For T2D patients, Aetna often requires evidence that the patient is on a basal insulin regimen specifically (not just oral agents) and that HbA1c remains above goal despite adequate titration. A 2019 Lancet Diabetes and Endocrinology meta-analysis of seven randomized trials (N=8,941) found degludec produced significantly fewer hypoglycemic episodes than glargine in T2D patients across all hypoglycemia severity categories, supporting the clinical argument for T2D cases as well.

Tresiba is not FDA-approved for weight loss, obesity management, or any indication outside of glycemic control in diabetes. Aetna will deny any PA submitted for off-label weight-loss indications categorically.

Practical Steps for Prescribers Submitting a Tresiba PA to Aetna

The following sequence reduces first-pass denial rates based on documented PA best practices and published insurer transparency data.

Step 1. Verify the patient's specific Aetna plan formulary before submitting. The base Aetna commercial formulary differs from employer-customized versions. Use the Aetna provider portal or NaviNet.

Step 2. Order and document a HbA1c within the past 90 days. Aetna routinely rejects PAs with lab data older than 90 days.

Step 3. Document prior basal insulin use explicitly: drug name, dose, duration, reason for inadequacy (hypoglycemia episodes with dates and glucose values, or documented HbA1c failure despite dose titration to manufacturer-recommended targets). The ADA titration guidelines specify that glargine U100 should be titrated to a fasting glucose of 80 to 130 mg/dL before being deemed inadequate.

Step 4. Cite DEVOTE (NEJM 2017, PMID 28605603) and the FDA prescribing information in the clinical letter.

Step 5. Use Aetna's standardized PA form if available, but attach the clinical letter as a separate document addressing each criterion. Generic PA form answers alone are insufficient for moderate-to-high difficulty requests.

Step 6. Confirm submission via Aetna's provider portal and document the reference number. Follow up at 48 hours if no acknowledgment is received. A 2022 JAMA Network Open study found that provider follow-up calls within 48 hours of PA submission reduced average decision time by 1.8 days.

Step 7. If denied, request the specific clinical denial criteria in writing. Aetna is required to provide these. Build the Level 1 appeal specifically around each stated denial reason.